Fish Oil Cuts Heart Failure Morbidity, Mortality

Nevertheless, he added, there remains “a bit of mystery” regarding the mechanism of benefit, as there was no significant reduction in sudden cardiac death or presumed arrhythmic death in the n-3 PUFA group. And the optimal dosage has yet to be defined, Dr. Komajda said.

GISSI-HF was simultaneously published online (Lancet 2008 Aug. 31 [doi:10.1016/50140–6736(08)61239–8]).

The trial was funded by the Società Prodotti Antibiotici S.p.A., Pfizer Inc., Sigma-Tau Pharmaceuticals Inc., and AstraZeneca Pharmaceuticals, which provided Dr. Tavazzi with research support and honoraria.

There was a significant adjusted 9% relative risk reduction in the n-3 PUFA group. DR. TAVAZZI